Effect of Nano-curcumin versus not receiving it on serum levels of Betatrophin and Irisin in patients with metabolic syndrome

Effect of Nano-curcumin versus not receiving it on serum levels of Betatrophin and Irisin in patients with metabolic syndrome: a before-after clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20120215009014N214

Enrollment

Registered

2018-03-19

Start date

2018-04-08

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic syndrome. Metabolic syndrome

Interventions

Intervention 1: Intervention group: Nano-curcumin tablet 80 mg daily for 2 months. Intervention 2: .

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Age: 18 to 70 years old Metabolic syndrome diagnosis

Exclusion criteria

Exclusion criteria: Diabetes Thyroid disease Liver disease Renal disease Using interfering drugs with carbohydrate and lipid metabolism

Design outcomes

Primary

Measure	Time frame
Measuring the serum levels of Betatrophin. Timepoint: Before intervention and 2 months later. Method of measurement: Through the laboratory test.;Measuring the serum levels of Irisin. Timepoint: Before intervention and 2 months later. Method of measurement: Through the laboratory test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Khodamoradi

Hamedan University of Medical Sciences

khodamoradizahra@gmail.com+98 81 3838 0283

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 13, 2026